THERAPY WITH PARENTERAL PAMIDRONATE PREVENTS THYROID HORMONE-INDUCED BONE TURNOVER IN HUMANS

被引:50
作者
ROSEN, HN
MOSES, AC
GUNDBERG, C
KUNG, VT
SEYEDIN, SM
CHEN, T
HOLICK, M
GREENSPAN, SL
机构
[1] BETH ISRAEL HOSP, CHARLES A DANA RES INST, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA
[2] BETH ISRAEL HOSP, DEPT MED, DIV GERONTOL, BOSTON, MA 02215 USA
[3] BETH ISRAEL HOSP, DEPT MED, DIV ENDOCRINOL, BOSTON, MA 02215 USA
[4] BETH ISRAEL HOSP, DEPT MED, DIV BONE & MINERAL METAB, BOSTON, MA 02215 USA
[5] YALE UNIV, SCH MED, DEPT ORTHOPED & REHABIL, NEW HAVEN, CT 06510 USA
[6] BOSTON UNIV, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02118 USA
[7] METRA BIOSYST, PALO ALTO, CA 94304 USA
关键词
D O I
10.1210/jc.77.3.664
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bisphosphonates have been shown to decrease bone turnover in a variety of high turnover states. We postulated that pamidronate (APD), a bisphosphonate, could prevent the increased bone turnover caused by thyroid hormone excess. Twenty-two male subjects were randomized to receive either placebo (group 1) or APD (30 mg, iv, daily for 2 days; group 2). Subsequently, all subjects received T3 (50 mug, twice daily, for 8 days). Biochemical indices of bone turnover were measured in blood and urine at baseline, after treatment with APD/placebo, and after treatment with T3. The urinary calcium/creatinine ratio (Uca/cr) fell significantly after treatment with APD, but not after treatment with placebo (group 1, 0.131 +/- 0.021; group 2, 0.040 +/- 0.013 mmol Ca/mmol Cr; P < 0.002). After treatment with T3, Uca/cr rose significantly in group 1, but not in group 2 (group 1, 0.275 +/- 0.042; group 2, 0.065 +/- 0.025 mmol Ca/mmol Cr; P < 0.05). Thus, APD prevented the rise in Uca/cr caused by treatment with T3. Similar results were obtained with urinary hydroxyproline and urinary pyridinoline cross-links. We conclude that 8 days of mild thyroid hormone excess in normal men increases bone turnover, and prior administration of APD prevents thyroid hormone-induced increases in bone resorption. APD may be useful in the prevention of thyroid hormone-induced osteopenia.
引用
收藏
页码:664 / 669
页数:6
相关论文
共 38 条
[1]   THYROID-HORMONES AND BONE MASS [J].
BARAN, DT ;
BRAVERMAN, LE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (06) :1182-1183
[2]   CALCIUM-METABOLISM IN THYROID-DISEASE [J].
BENKER, G ;
BREUER, N ;
WINDECK, R ;
REINWEIN, D .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1988, 11 (01) :61-69
[3]   A METHOD FOR THE DETERMINATION OF THE CIRCULATING CONCENTRATION OF 1,25-DIHYDROXYVITAMIN-D [J].
CHEN, TC ;
TURNER, AK ;
HOLICK, MF .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 1990, 1 (06) :320-327
[4]   METHODS FOR THE DETERMINATION OF THE CIRCULATING CONCENTRATION OF 25-HYDROXYVITAMIN-D [J].
CHEN, TC ;
TURNER, AK ;
HOLICK, MF .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 1990, 1 (06) :315-319
[5]   ESTROGEN MAINTAINS TRABECULAR BONE VOLUME IN RATS NOT ONLY BY SUPPRESSION OF BONE-RESORPTION BUT ALSO BY STIMULATION OF BONE-FORMATION [J].
CHOW, J ;
TOBIAS, JH ;
COLSTON, KW ;
CHAMBERS, TJ .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (01) :74-78
[6]  
CHRISTIANSEN C, 1985, LANCET, V2, P800
[7]  
COOK J G H, 1975, Annals of Clinical Biochemistry, V12, P219
[8]   NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA [J].
DEGROOT, LJ ;
KAPLAN, EL ;
MCCORMICK, M ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :414-424
[9]   COMPARATIVE-STUDY OF PAMIDRONATE DISODIUM AND ETIDRONATE DISODIUM IN THE TREATMENT OF CANCER-RELATED HYPERCALCEMIA [J].
GUCALP, R ;
RITCH, P ;
WIERNIK, PH ;
SARMA, PR ;
KELLER, A ;
RICHMAN, SP ;
TAUER, K ;
NEIDHART, J ;
MALLETTE, LE ;
SIEGEL, R ;
VANDEPOL, CJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :134-142
[10]  
GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P516